Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Concurrent administration of BCMA and GPRC5D CAR T cells in advanced myeloma yields ORR of 78% w/ median PFS of 18.2 months; correlative analysis suggests that antigen loss may still be an important mechanism of resistance.”
Title: Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma
Authors: Sham Mailankody, Sneha Mitra, Kevin Herrera, Bachisio Ziccheddu, Briana Cadzin, Ozgur Can Eren, Tasmin Farzana, Tahmin Ullah, Jonathan Landa, Andriy Derkach, Jagrutiben Chaudhari, Devin McAvoy, Kinga Hosszu, Gunjan L. Shah, Heather J. Landau, Francesco Maura, Ahmet Dogan, Sergio A. Giralt, Xiuyan Wang, Michel Sadelain, Eric L. Smith, Renier J. Brentjens, Christina S. Leslie, Saad Z. Usmani, Karlo Perica
You can read the Full Article on Blood.
You can find other articles featuring Robert Orlowski on OncoDaily.
